News
Farmacon global corporate social responsability plan to benefit rare disease patients.
“During this season of giving, Farmacon Global is pleased to announce LINK, our 2022 corporate social responsibility pro gram,” said Sara Tylosky, CEO Farmacon Global.
Farmacon Global Newsbrief August 23
“We are not just talking about Biopharma Industries’ possibilities in these emerging markets,” said Sara Tylosky, CEO Farmacon Global. “It’s also about opportunities for patients
A Leadership Role in Latin America
Rare Disease patients are the key to new treatment development, and Latin America is no exception. On July 14th, 2021, Farmacon Global implemented another successful
Save the Date for Farmacon Global and USC San Diego Extension’s Rare Disease Assembly, September 9th, 2021.
“This year our Rare Disease Assembly, called ‘Rare Diem – Seizing Opportunities for Rare Diseases in EmergingMarkets’ will be virtual,” said Sara Tylosky, CEO, Farmacon
Engagement That Elevates the Patient’s Voice.
“We’ll be looking at the problem of rare disease challenges from the inside out,” said Antoine Daher, founder of Casa Hunter, president of Febrararas, the
Positive mid-stage results for Medicago’s plant-derived COVID-19 vaccine.
“It’s rewarding to find an article like this and know that you and your specialized team are helping to bring suchan important trial to fruition.